The IL - 6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis

Journal of Cellular and Molecular Medicine

Volumn 10, Issue 4, 2006, Pages 890-895

  Sfrent Cornateanu, Roxana ^a   Mihai, Carina ^a   Balan, Simona ^b   Ionescu, R ^a   Moldoveanu, E ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Cytokine; Fibrosis; Gene polymorphism; Interleukin 6 (IL 6); Systemic sclerosis (SSc)

Indexed keywords

EID: 84867200145     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.2755/jcmm010.004.08     Document Type: Article

References (28)

1. Maricq HR, Weinrich MC, Keil JL. Prevalence of scleroderma spectrum disorders in the general population of Southern Carolina. Arthritis Rheum. 1989; 32: 998-1006.
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004; 140: 37-50.
3. Kissin EY, Korn JH. Fibrosis in scleroderma. Rhem Dis Clin N Am 2003; 29: 351-69.
4. Zurita-Salinas CS, Richaud-Patin Y. Spontaneous cytokine gene expression by cultured fibroblasts of systemic sclerosis. Correlation with collagen synthesis. Rev Invest Clin. 1998; 50: 97-104.
5. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-lalpha from SSc fibroblasts induces IL-6 and PDGF-A. J Clin Invest. 1999; 103: 1253-60.
6. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol. 2004; 16: 739-45.
7. Bodolay E., Koch A.E., Kim J., Szegedi G., Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J. Cell. Mol. Med. 2002. 6: 357-76.
8. Hasegawa M, Sato S, Fujimoto M. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998; 25: 308-13.
9. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001; 27: 140-6.
10. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999; 38: 612-7.
11. Giacomelli R, Cipriani P, Danese C. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol. 1996; 23: 291-6.
12. Takemura H, Suzuki H, Fujisawa H. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol. 1998; 25: 1534-9.
13. Kadono T, Kikuchi K, Ihn H. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol. 1998; 25: 296-301.
14. Osiri M, McNicholl J, Moreland LW, Bridges SL. A novel single nucleotide polymorphism and five probable haplotypes in the 5' flanking region of the IL-6 gene in African-Americans. Genes Immun. 1999; 1: 66-7.
15. Pola R, Gaetani E, Flex A. -174 G/C interleukin-6 gene polymorphism and increased risk of multi-infarct dementia: a case-control study. Exp Gerontol. 2002; 37: 949-55.
16. Fernandez-Real JM, Broch M, Vendrell J. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49: 517-20.
17. Schotte H, Schluter B, Rust S. Interleukin-6 promoter polymorphism (-174G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology 2001; 40: 393-400.
18. Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The -597 G→A and -174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab. 2002; 87: 1134-41.
19. Fedetz M, Matesanz F, Pascual M. The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neurol Sci., 2001; 190: 69-72.
20. Vasku A, Soucek M, Goldbergova M, Vacha J. Office blood pressure, heart rate and A(-596)G interleukin-6 gene polymorphism in apparently healthy Czech middle-aged population. Physiol Res. 2003; 52: 291-7.
21. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun. 2000; 1: 338-40.
22. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-76.
23. LeRoy EC, Black C, Fleischmajer R, Jolonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): Classicfication, subsets and pathogenesis. J. Rheumatol. 1988: 15: 202-5.
24. European Scleroderma Study Group: Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol. 2003; 21: S39-41.
25. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21: S42-6.
26. Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales tro demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997; 40: 1984-91.
27. Yoshida M, Sakuma J, Hayashi S. A histological distinctive interstitial pneumonia induced by over expression of the interleukin 6, transforming growth factor B gene. Proc Natl Acad Sci. USA. 1995; 92: 9570-4.
28. Hulkkonen J, Petrovaara M, Antonen J. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL-6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology 2001; 40: 656-61.